Center for Clinical and Cosmetic Research
Aventura, Florida, 33180, United States
Location status: Recruiting
Location contact
Clinical Research Coordinator
CONTACT
Mark S Nestor, M.D., Ph.D.
PRINCIPAL_INVESTIGATOR
Mark S. Nestor, MD, PhD
CONTACT
NCT Number: NCT06577311
The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive gel used in combination with a light source.
The main questions this trial aims to answer are:
* to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and; * seeing how many participants had no remaining affected facial skin cancer sections after treatment.
Participants who qualify will be asked to complete 14 visits in total and will receive a total of two treatments, after voluntarily consent has been given.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Aventura, Florida, 33180, United States
Location status: Recruiting
Clinical Research Coordinator
CONTACT
Mark S Nestor, M.D., Ph.D.
PRINCIPAL_INVESTIGATOR
Mark S. Nestor, MD, PhD
CONTACT
In the study, participants will be asked to complete the following:
To qualify for this trial, participants must:
All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing. All photographs of the treatment area collected during the study will be used as study data.
All participants have the right to refuse further participation in the study at any time.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®), followed by red light therapy administered for 13 minutes and 30 seconds to deliver the total desired light dose to the SCCis lesion.
Other names: Ameluz ®, RhodoLED-XL®
Time frame: an average of 12 weeks
Histological clearance is defined as the absence of detectable evidence of SCCis tumor cell nests by the central pathology reports
Time frame: an average of 12 weeks
Complete Clinical Clearance will be measured by the Investigator and is defined as when there is no clinically visible lesion remaining at the site
Time frame: Up to 16 weeks
Changes noted in the size of the treated SCCis lesion site, measured by the longest diameter.
Time frame: Up to 16 weeks
Observations and changes noted in the aesthetic appearance (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/ Pustulation, Erosion/ Ulceration) of thetreated isSCC lesion will each be graded on a scale of 0 to 4, with 0 as no presenceand 4 as a severe outcome.
Contact information is provided by the study sponsor or research team.
The Center for Clinical and Cosmetic Research
Other
An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10% (Ameluz ®) With RhodoLED-XL® Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)"
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05859074
Adenocarcinoma, Adenocarcinoma, Sebaceous
Basking Ridge, New Jersey, United States
View Trial DetailsNCT05574101
Carcinoma, Carcinoma, Squamous Cell
Aurora, Colorado, United States
View Trial DetailsNCT05482880
Behavior, Carcinoma
Nijmegen, Gelderland, Netherlands
View Trial DetailsNCT06046625
Behavior, Carcinoma
Maastricht, Netherlands
View Trial Details